Evaluate Efficacy, Safety and Tolerability of JTT-861 in Subjects With Heart Failure With Reduced Ejection Fraction

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 314 participants.

Also called NCT06017609

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 314 participants (enrolled count) (from the registry)
Sponsor
Shionogi Inc. (from the registry)
Registry
  • NCT NCT06017609
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Bulgaria, Czechia, Poland, Romania, Spain (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06017609. Randomized; quadruple masking; primary purpose treatment. Start 2023-12-20 (actual); primary completion 2026-05-18 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluate Efficacy, Safety and Tolerability of JTT-861 in Subjects With Heart Failure With Reduced Ejection Fraction
Acronym
POWER-HF
Condition
Chronic Heart Failure
Intervention (Drug)
JTT-861 Capsules
Intervention (Drug)
Placebo Capsules
Lead sponsor
Shionogi Inc. (class: industry)
Collaborator
ICON Clinical Research (class: industry)

Record details

Record id
cardio:ct-nct06017609
Content hash
ad432f8f0e685406fd14fb963d79994dec23e13e66d20d9dfe2831a9bd7c6c58